Zoetis Inc

NYSE ZTS

Download Data

Zoetis Inc Depreciation and Amortization 3 year CAGR for the year ending December 31, 2023: 3.64%

Zoetis Inc Depreciation and Amortization 3 year CAGR is 3.64% for the year ending December 31, 2023, a -11.45% change year over year. Depreciation and Amortization involve the systematic allocation of the cost of tangible and intangible assets over their useful lives. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Zoetis Inc Depreciation and Amortization for the year ending December 31, 2022 was USD 465.00 M, a 3.79% change year over year.
  • Zoetis Inc Depreciation and Amortization for the year ending December 31, 2021 was USD 448.00 M, a 1.59% change year over year.
  • Zoetis Inc Depreciation and Amortization for the year ending December 31, 2020 was USD 441.00 M, a 7.04% change year over year.
  • Zoetis Inc Depreciation and Amortization for the year ending December 31, 2019 was USD 412.00 M, a 33.77% change year over year.
NYSE: ZTS

Zoetis Inc

CEO Ms. Kristin C. Peck
IPO Date Feb. 1, 2013
Location United States
Headquarters 10 Sylvan Way, Parsippany, NJ, United States, 07054
Employees 14,100
Sector Healthcare
Industry Drug manufacturers - specialty & generic
Description

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

Similar companies

EBS

Emergent Biosolutions Inc

NA

NA

TEVA

Teva Pharma Industries Ltd ADR

NA

NA

CTLT

Catalent Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email